PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
STRO vs. RNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between STRO and RNA is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

STRO vs. RNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sutro Biopharma, Inc. (STRO) and Avidity Biosciences, Inc. (RNA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%SeptemberOctoberNovemberDecember2025February
-58.68%
-26.59%
STRO
RNA

Key characteristics

Sharpe Ratio

STRO:

-0.73

RNA:

1.76

Sortino Ratio

STRO:

-1.07

RNA:

2.60

Omega Ratio

STRO:

0.88

RNA:

1.31

Calmar Ratio

STRO:

-0.68

RNA:

2.01

Martin Ratio

STRO:

-1.59

RNA:

6.76

Ulcer Index

STRO:

40.42%

RNA:

18.82%

Daily Std Dev

STRO:

88.56%

RNA:

71.60%

Max Drawdown

STRO:

-94.15%

RNA:

-86.45%

Current Drawdown

STRO:

-93.68%

RNA:

-37.10%

Fundamentals

Market Cap

STRO:

$134.00M

RNA:

$4.09B

EPS

STRO:

-$1.55

RNA:

-$2.83

Total Revenue (TTM)

STRO:

$47.23M

RNA:

$7.92M

Gross Profit (TTM)

STRO:

-$16.55M

RNA:

$6.60M

EBITDA (TTM)

STRO:

-$127.28M

RNA:

-$256.60M

Returns By Period

In the year-to-date period, STRO achieves a -5.43% return, which is significantly lower than RNA's 13.55% return.


STRO

YTD

-5.43%

1M

1.16%

6M

-56.93%

1Y

-60.63%

5Y*

-31.01%

10Y*

N/A

RNA

YTD

13.55%

1M

22.07%

6M

-27.41%

1Y

144.41%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

STRO vs. RNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

STRO
The Risk-Adjusted Performance Rank of STRO is 99
Overall Rank
The Sharpe Ratio Rank of STRO is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of STRO is 99
Sortino Ratio Rank
The Omega Ratio Rank of STRO is 1212
Omega Ratio Rank
The Calmar Ratio Rank of STRO is 99
Calmar Ratio Rank
The Martin Ratio Rank of STRO is 33
Martin Ratio Rank

RNA
The Risk-Adjusted Performance Rank of RNA is 8787
Overall Rank
The Sharpe Ratio Rank of RNA is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of RNA is 8888
Sortino Ratio Rank
The Omega Ratio Rank of RNA is 8484
Omega Ratio Rank
The Calmar Ratio Rank of RNA is 9090
Calmar Ratio Rank
The Martin Ratio Rank of RNA is 8585
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

STRO vs. RNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sutro Biopharma, Inc. (STRO) and Avidity Biosciences, Inc. (RNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for STRO, currently valued at -0.73, compared to the broader market-2.000.002.004.00-0.731.76
The chart of Sortino ratio for STRO, currently valued at -1.07, compared to the broader market-6.00-4.00-2.000.002.004.006.00-1.072.60
The chart of Omega ratio for STRO, currently valued at 0.88, compared to the broader market0.501.001.502.000.881.31
The chart of Calmar ratio for STRO, currently valued at -0.68, compared to the broader market0.002.004.006.00-0.682.01
The chart of Martin ratio for STRO, currently valued at -1.59, compared to the broader market0.0010.0020.0030.00-1.596.76
STRO
RNA

The current STRO Sharpe Ratio is -0.73, which is lower than the RNA Sharpe Ratio of 1.76. The chart below compares the historical Sharpe Ratios of STRO and RNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.0010.00SeptemberOctoberNovemberDecember2025February
-0.73
1.76
STRO
RNA

Dividends

STRO vs. RNA - Dividend Comparison

Neither STRO nor RNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

STRO vs. RNA - Drawdown Comparison

The maximum STRO drawdown since its inception was -94.15%, which is greater than RNA's maximum drawdown of -86.45%. Use the drawdown chart below to compare losses from any high point for STRO and RNA. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-93.68%
-37.10%
STRO
RNA

Volatility

STRO vs. RNA - Volatility Comparison

Sutro Biopharma, Inc. (STRO) has a higher volatility of 23.28% compared to Avidity Biosciences, Inc. (RNA) at 13.97%. This indicates that STRO's price experiences larger fluctuations and is considered to be riskier than RNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
23.28%
13.97%
STRO
RNA

Financials

STRO vs. RNA - Financials Comparison

This section allows you to compare key financial metrics between Sutro Biopharma, Inc. and Avidity Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab